Endovascular treatment of complex diseases of the thoracic aorta-10 years single centre experience.
Thoracic aorta
aortic aneurysm
aortic dissection
endovascular treatment
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
3
8
2019
pubmed:
3
8
2019
medline:
3
8
2019
Statut:
ppublish
Résumé
Introduction of invasive endovascular techniques constituted a real a breakthrough in the treatment of aortic aneurysm dissection and rupture. We assessed the effectiveness and safety of thoracic endovascular aortic repair (TEVAR) in patients with thoracic aortic pathologies. Between 2007 and 2017, 118 patients with thoracic aortic pathology underwent TEVAR. Among them, 20 (16.9%) patients required hybrid procedures. Stent grafts indication were thoracic aortic aneurysm in 46 (39.0%) patients, type B dissection in 68 (57.6%) patients and other indications in 4 (3.3%). Procedural success rate, in-hospital and late mortality and morbidity were evaluated. The patients were followed-up for a mean of 55 months (range, 6-118 months). The technical success rate was 96%. Five patients died during the first 30 days after procedure (mortality 4.2%), four due to ischemic stroke followed by multi-organ failure and another one hemodynamically significant type I endoleak. Most of them were noted in the first years of our study. Five others died during post-discharged period. Four patients developed neurological complications, including stroke (n=2; 1.7%) and paraparesis (n=2; 1.7%). There were 6 (5.1%) primary (5 type I and 1 type II) and 3 (2.5%) secondary endoleaks (1 type I and 2 type III). Secondary interventions were required in 8 subjects. There was one case of stent collapse and two retrograde aortic dissection. Treatment of descending aortic diseases by using stent graft implantation has become the method of choice, decreasing the risk of open surgery, especially in patients with severe clinical state and comorbidities. However, effectiveness and safety may be achieved by experience team.
Sections du résumé
BACKGROUND
BACKGROUND
Introduction of invasive endovascular techniques constituted a real a breakthrough in the treatment of aortic aneurysm dissection and rupture. We assessed the effectiveness and safety of thoracic endovascular aortic repair (TEVAR) in patients with thoracic aortic pathologies.
METHODS
METHODS
Between 2007 and 2017, 118 patients with thoracic aortic pathology underwent TEVAR. Among them, 20 (16.9%) patients required hybrid procedures. Stent grafts indication were thoracic aortic aneurysm in 46 (39.0%) patients, type B dissection in 68 (57.6%) patients and other indications in 4 (3.3%). Procedural success rate, in-hospital and late mortality and morbidity were evaluated.
RESULTS
RESULTS
The patients were followed-up for a mean of 55 months (range, 6-118 months). The technical success rate was 96%. Five patients died during the first 30 days after procedure (mortality 4.2%), four due to ischemic stroke followed by multi-organ failure and another one hemodynamically significant type I endoleak. Most of them were noted in the first years of our study. Five others died during post-discharged period. Four patients developed neurological complications, including stroke (n=2; 1.7%) and paraparesis (n=2; 1.7%). There were 6 (5.1%) primary (5 type I and 1 type II) and 3 (2.5%) secondary endoleaks (1 type I and 2 type III). Secondary interventions were required in 8 subjects. There was one case of stent collapse and two retrograde aortic dissection.
CONCLUSIONS
CONCLUSIONS
Treatment of descending aortic diseases by using stent graft implantation has become the method of choice, decreasing the risk of open surgery, especially in patients with severe clinical state and comorbidities. However, effectiveness and safety may be achieved by experience team.
Identifiants
pubmed: 31372261
doi: 10.21037/jtd.2019.06.26
pii: jtd-11-06-2240
pmc: PMC6626816
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2240-2250Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Ann Vasc Surg. 2017 May;41:294-299
pubmed: 28242407
J Endovasc Ther. 2012 Apr;19(2):213-25
pubmed: 22545887
J Endovasc Ther. 2016 Aug;23(4):634-41
pubmed: 27225214
Ann Thorac Surg. 2002 Nov;74(5):S1833-5; discussion S1857-63
pubmed: 12440675
J Thorac Dis. 2017 Nov;9(11):4477-4485
pubmed: 29268517
Semin Vasc Surg. 2000 Dec;13(4):290-8
pubmed: 11156057
J Vasc Surg. 2011 Jan;53(1):193-199.e1-21
pubmed: 21035988
J Card Surg. 2016 Mar;31(3):164-7
pubmed: 26786056
Eur J Vasc Endovasc Surg. 2001 Oct;22(4):342-7
pubmed: 11563894
Ann Thorac Surg. 2009 Feb;87(2):603-7
pubmed: 19161789
J Vasc Surg. 2002 Dec;36(6):1121-8
pubmed: 12469042
J Vasc Surg. 2006 Mar;43(3):433-9
pubmed: 16520151
J Endovasc Ther. 2005 Feb;12(1):89-97
pubmed: 15683277
Eur J Radiol. 2001 Jul;39(1):42-9
pubmed: 11439230
J Interv Cardiol. 2006 Dec;19(6):539-43
pubmed: 17107369
Ann Thorac Surg. 2007 May;83(5):1628-33; discussion 1633-4
pubmed: 17462370
N Engl J Med. 1999 May 20;340(20):1546-52
pubmed: 10332016
Am J Cardiol. 2008 Nov 15;102(10):1399-406
pubmed: 18993163
J Vasc Surg. 2001 Dec;34(6):997-1003
pubmed: 11743551
Eur J Vasc Endovasc Surg. 2012 Mar;43(3):269-75
pubmed: 22240331
Eur J Cardiothorac Surg. 2001 Feb;19(2):203-13
pubmed: 11167113
J Vasc Surg. 2006 May;43(5):1045-8
pubmed: 16678702
Vestn Khir Im I I Grek. 1986 Nov;137(11):123-5
pubmed: 3824776
J Vasc Surg. 2006 Mar;43(3):609-12
pubmed: 16520181
Ann Thorac Surg. 2008 Nov;86(5):1524-9
pubmed: 19049743
Ann Thorac Surg. 2008 Jan;85(1 Suppl):S1-41
pubmed: 18083364
Ann Thorac Surg. 2005 Sep;80(3):857-63; discussion 863
pubmed: 16122443
J Vasc Surg. 2006 Jan;43(1):14-8
pubmed: 16414381
Eur J Vasc Endovasc Surg. 2008 Apr;35(4):455-61
pubmed: 18180183
Eur J Cardiothorac Surg. 2006 May;29(5):709-13
pubmed: 16520043
Ann Vasc Surg. 2001 Sep;15(5):563-6
pubmed: 11665442
Eur Heart J. 2015 Nov 1;36(41):2779
pubmed: 26129948
J Vasc Surg. 2006 Feb;43 Suppl A:85A-88A
pubmed: 16473178
N Engl J Med. 1999 May 20;340(20):1539-45
pubmed: 10332015
Ann Surg. 2010 Oct;252(4):603-10
pubmed: 20881766
J Vasc Surg. 2006 Oct;44(4):688-93
pubmed: 16926086
Semin Intervent Radiol. 2009 Mar;26(1):3-9
pubmed: 21326525
J Vasc Surg. 2007 Jan;45(1):90-4; discussion 94-5
pubmed: 17210389
J Thorac Cardiovasc Surg. 2010 Nov;140(5):1001-10
pubmed: 20951252
Lancet. 2004 Sep 4-10;364(9437):843-8
pubmed: 15351191
J Thorac Cardiovasc Surg. 2008 May;135(5):1103-9, 1109.e1-4
pubmed: 18455591
Circulation. 2009 Dec 22;120(25):2519-28
pubmed: 19996018
N Engl J Med. 1994 Dec 29;331(26):1729-34
pubmed: 7984192
JACC Cardiovasc Interv. 2008 Aug;1(4):395-402
pubmed: 19463336
J Vasc Surg. 2005 Jul;42(1):11-7
pubmed: 16012446
Br J Radiol. 2005 Oct;78(934):906-12
pubmed: 16177013
Circ Cardiovasc Interv. 2013 Aug;6(4):407-16
pubmed: 23922146
J Endovasc Ther. 2004 Oct;11(5):535-8
pubmed: 15482026
J Vasc Surg. 2002 May;35(5):1048-60
pubmed: 12021727
J Endovasc Ther. 2002 Jun;9 Suppl 2:II98-105
pubmed: 12166849
J Endovasc Surg. 1999 May;6(2):136-46
pubmed: 10473331
J Thorac Cardiovasc Surg. 2010 Jul;140(1):52-8
pubmed: 19919865
J Vasc Surg. 1997 Jan;25(1):165-72
pubmed: 9013921
J Thorac Cardiovasc Surg. 2010 May;139(5):1153-7
pubmed: 19660344
Langenbecks Arch Surg. 2012 Dec;397(8):1267-73
pubmed: 22956054
J Vasc Surg. 2018 Dec;68(6S):14S-21S.e2
pubmed: 30064843
Ann Thorac Surg. 1999 Feb;67(2):593-4
pubmed: 10197712
J Vasc Surg. 1999 Feb;29(2):292-305; discussion 306-8
pubmed: 9950987
Circulation. 2008 Aug 19;118(8):808-17
pubmed: 18678769